← All trials
NCT06041477
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2023
- Primary completion
- Jul 31, 2027
- Completion date
- Jul 31, 2030
- First posted
- Sep 18, 2023
- Last posted
- Sep 18, 2023
- Enrollment
- 540
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- First People's Hospital of FoshanCollaborator
- Guangzhou UniversityCollaborator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityReponsible party - principal investigator
- Guangdong Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.